abrdn plc Purchases 16,612 Shares of Humana Inc. (NYSE:HUM)

abrdn plc increased its position in Humana Inc. (NYSE:HUM) by 15.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 125,860 shares of the insurance provider’s stock after buying an additional 16,612 shares during the period. abrdn plc owned about 0.10% of Humana worth $31,941,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Creative Financial Designs Inc. ADV lifted its stake in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in Humana in the 3rd quarter worth $31,000. Your Advocates Ltd. LLP lifted its stake in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. Atwood & Palmer Inc. lifted its stake in Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares in the last quarter. Finally, LRI Investments LLC lifted its stake in Humana by 1,021.4% in the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after purchasing an additional 143 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of HUM stock opened at $290.52 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $34.98 billion, a P/E ratio of 25.73, a P/E/G ratio of 2.21 and a beta of 0.56. The company’s 50-day simple moving average is $275.13 and its two-hundred day simple moving average is $299.72. Humana Inc. has a one year low of $213.31 and a one year high of $406.46.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on HUM shares. TD Cowen boosted their price target on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Morgan Stanley upped their target price on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Wells Fargo & Company decreased their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and upped their target price for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Finally, Piper Sandler upped their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.